Prostatype Genomics AB Sustainability Reports
Prostatype Genomics AB manufactures, markets, and sells prognostic gene tests for prostate cancer. Its Prostatype Test System combines gene expression data with clinical parameters to help doctors and patients evaluate tumor aggressiveness and make informed treatment decisions.
Sector: Professional & technical services
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 549300JO6MPCGPVHVU91
FIGI: BBG00XGCF925
12 reports from 2020 to 2025
